menu
    • menu
    [{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kindred Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kindred Biosciences \/ Vaxart","highestDevelopmentStatusID":"4","companyTruncated":"Kindred Biosciences \/ Vaxart"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Dechra Pharmaceuticals Manufacturing","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor | Adrenergic receptor alpha-2","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Kindred Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing","highestDevelopmentStatusID":"15","companyTruncated":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Elanco","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"KIND-030","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kindred Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Kindred Biosciences \/ Elanco","highestDevelopmentStatusID":"10","companyTruncated":"Kindred Biosciences \/ Elanco"}]

    Find Clinical Drug Pipeline Developments & Deals by Kindred Biosciences

    Menu

    Kindred Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kindred Biosciences

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Kindred Biosciences

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KIND-030

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Elanco

                            Deal Size : $16.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal ...

                            Details : The collaboration grants Elanco Animal Health an exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus. Under the agreement, KindredBio also has a right of last refusal to manufacture certain of Elanco's other monoclonal ...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $0.5 million

                            December 11, 2020

                            Lead Product(s) : KIND-030

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Elanco

                            Deal Size : $16.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kindred Biosciences

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Kindred Biosciences

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Vaxart

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart

                            Details : Under the terms of the agreement, KindredBio will provide manufacturing services for the manufacture of Vaxart 's oral vaccine candidate for COVID-19 from its state-of-the-art biological development and cGMP production facility in Burlingame, CA.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 20, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Vaxart

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kindred Biosciences

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Kindred Biosciences

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Dechra Pharmaceuticals Manufacturing

                            Deal Size : $43.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction

                            Details : The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $43.0 million

                            March 16, 2020

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Dechra Pharmaceuticals Manufacturing

                            Deal Size : $43.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth